Study of NGR-hTNF Administered at High Doses in Patient With Advanced or Metastatic Solid Tumour

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00878111
Recruitment Status : Unknown
Verified October 2015 by MolMed S.p.A..
Recruitment status was:  Active, not recruiting
First Posted : April 8, 2009
Last Update Posted : October 9, 2015
Information provided by (Responsible Party):
MolMed S.p.A.

Brief Summary:

The main objective of the trial is to document the safety and antivascular effect of escalating doses of NGR-hTNF, from 60 mcg/sqm to 325 mcg/sqm, in patients affected by advanced or metastatic solid tumors not amenable of standard therapies.

Safety will be established by clinical and laboratory assessment according to NCI-CTCAE criteria (version 4.02).

Condition or disease Intervention/treatment Phase
Solid Tumors Drug: NGR-hTNF Phase 1

Detailed Description:

Pre-clinical studies provide the support that NGR-TNF is endowed with a higher therapeutic index in animal models and studies of the mechanism of action showed that NGR-TNF can induce tumour necrosis when used at relatively high doses.

Recently, a phase I dose-escalation study of NGR-hTNF has explored the dose range between 0.2 and 60 µg/m2, showing DLT at 60 mcg/m2 experienced as transient acute infusion reaction few minutes after the first administration start. Considering the relationship with the infusion of these events, a further dose escalation will be explored in the present phase I study by using both a longer infusion time (i.e., 120 minutes instead of 60 minutes) and a mild premedication.

The first cohort (n=4) of patients will be treated with NGR-hTNF administered at 60 mcg/m2 IV every three weeks, that is a dose level 33% higher than MTD and recommended dose selected in the previous phase I trial (i.e., 45 mcg/m2). If ≤1 of 4 patients experience DLT during the first cycle, following cohorts will be treated with escalating doses (from 80 to 325 mcg/m2) of NGR-hTNF IV every three weeks.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 48 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: NGR013: Phase I and Pharmacodynamic Study of NGR-hTNF Administered at High Doses in Patients With Advanced or Metastatic Solid Tumour
Study Start Date : April 2009
Estimated Primary Completion Date : June 2016
Estimated Study Completion Date : June 2016

Arm Intervention/treatment
Experimental: A: escalating dose levels of NGR-hTNF
NGR-hTNF administered at high doses
Drug: NGR-hTNF

First cohort: iv q3W 60 mcg/sqm over 120 min*

Second cohort: iv q3W 80 mcg/sqm over 120 min*

Third cohort: iv q3W 100 mcg/sqm over 120 min*

Fourth cohort: iv q3W 125 mcg/sqm over 120 min*

Fifth cohort: iv q3W 150 mcg/sqm over 120 min*

Sixth cohort: iv q3W 175 mcg/sqm over 120 min*

Seventh cohort: iv q3W 200 mcg/sqm over 120 min*

Eighth cohort: iv q3W 225 mcg/sqm over 120 min*

Ninth cohort: iv q3w 250 mcg/sqm over 120 min*

Tenth cohort: iv q3w 275 mcg/sqm over 120 min*

Eleventh cohort: iv q3w 300 mcg/sqm over 120 min*

Twelfth cohort: iv q3w 325 mcg/sqm over 120 min*

* If the first infusion is well-tolerated, the second infusion may be delivered over 90 minutes. If the 90-minute infusion is well tolerated, all subsequent infusions may be delivered over a 60-minute period.

Primary Outcome Measures :
  1. Optimal Biologic Dose (OBD) [ Time Frame: Before treatment, every 3-6 wks and end of treatment ]
    Evaluating both the safety in terms of maximum tolerated dose (MTD) and the antivascular effect in terms of changes documented with dynamic imaging (DCE-MRI)

Secondary Outcome Measures :
  1. Pharmacokinetic [ Time Frame: Several time points after 1^st, 2^nd and 3^rd administration ]
    Evaluation of plasma levels of sTNF-RI and sTNF-RII and anti-NGR-hTNF antibodies

  2. Preliminary antitumor activity [ Time Frame: Every 6 wks ]
    In terms of objective response rate according to RECIST criteria, progression-free and overall survival.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Patients ≥18 years with selected metastatic solid tumours recognized to be highly vascularised and not amenable to any clinical improvement by current standard treatments

    • Colorectal cancer (CRC) patients previously resistant to standard systemic regimens (including biologic agents)
    • Gastric cancer (GC) patients treated with no more than two standard systemic regimens for metastatic disease
    • Hepatocellular carcinoma (HCC) patients previously resistant to standard systemic regimens
    • Pancreatic carcinoma (PC) patients treated with no more than one standard systemic regimen for metastatic disease
    • Non small cell lung carcinoma (NSCLC) patients treated with no more than two standard systemic regimens (including biologic agents) for metastatic disease
    • Neuroendocrine (NE) tumours refractory to somatostatin analogue treatment
    • Other rare tumours including malignant pleural mesothelioma (MPM), soft-tissue sarcoma (STS), and renal cell carcinoma (RCC), resistant/refractory to current standard treatments
  • Life expectancy more than 3 months
  • ECOG Performance status 0-1
  • Adequate baseline bone marrow, hepatic and renal function, defined as follows:

    • Neutrophils >1.5 x 10^9/L and platelets > 100 x 10^9/L
    • Bilirubin <1.5 x ULN
    • AST and/or ALT <2.5 x ULN in absence of liver metastasis
    • AST and/or ALT <5 x ULN in presence of liver metastasis
    • Serum creatinine <1.5 x ULN
    • Creatinine clearance (estimated according to Cockcroft-Gault formula) ≥ 50 ml/min
  • Patients may have had prior therapy providing the following conditions are met before treatment start:

    • Chemotherapy, radiation therapy, hormonal therapy, or immunotherapy: wash-out period of 28 days
    • Surgery: wash-out period of 14 days
  • Patients must give written informed consent to participate in the study.

Exclusion Criteria:

  • Concurrent anticancer therapy
  • Patients must not receive any other investigational agents while on study
  • Patients with myocardial infarction within the last six (6) months, unstable angina, New York Heart Association (NYHA) grade II or greater congestive heart failure, or serious cardiac arrhythmia requiring medication
  • Uncontrolled hypertension
  • Prolonged QTc interval (congenital or acquired) > 450 ms
  • Patient with significant peripheral vascular disease
  • History or evidence upon physical examination of CNS disease unless adequately treated (e.g., primary brain tumor, any brain metastasis, seizure not controlled with standard medical therapy), or history of stroke
  • Patients with active or uncontrolled systemic disease/infections or with serious illness or medical conditions, which is incompatible with the protocol
  • Known hypersensitivity/allergic reaction or contraindications to human albumin preparations or to any of the excipients
  • Any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol
  • Pregnancy or lactation. Patients - both males and females - with reproductive potential (i.e. menopausal for less than 1-year and not surgically sterilized) must practice effective contraceptive measures throughout the study. Women of child-bearing potential must provide a negative pregnancy test (serum or urine) within 14 days prior to registration.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00878111

Istituto Clinico Humanitas
Rozzano, Milan, Italy, 20089
Sponsors and Collaborators
MolMed S.p.A.
Study Director: Antonio Lambiase, MD MolMed S.p.A.

Responsible Party: MolMed S.p.A. Identifier: NCT00878111     History of Changes
Other Study ID Numbers: NGR013
2008-000816-33 ( EudraCT Number )
First Posted: April 8, 2009    Key Record Dates
Last Update Posted: October 9, 2015
Last Verified: October 2015

Keywords provided by MolMed S.p.A.:
Solid tumours
High doses